# Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects

> **NCT00983099** · PHASE1 · COMPLETED · sponsor: **Merz Pharmaceuticals GmbH** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Neramexane

## Key facts

- **NCT ID:** NCT00983099
- **Lead sponsor:** Merz Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2011-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00983099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00983099, "Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00983099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*